Literature DB >> 23449480

Treatment of aniridia with Boston type I keratoprosthesis.

Jordan J Rixen1, Alex W Cohen, Anna S Kitzmann, Michael D Wagoner, Kenneth M Goins.   

Abstract

PURPOSE: To report the outcomes of Boston keratoprosthesis (K-pro) type I implantation for congenital aniridia.
METHODS: A retrospective review of the medical records of every patient with congenital aniridia who underwent Boston K-pro type I implantation at the University of Iowa Hospitals and Clinics from January 1, 2009, through December 31, 2011 was performed. The main outcome measures were visual acuity, graft retention, and postoperative complications.
RESULTS: A total of 7 eyes (7 patients) met the inclusion criteria. The mean patient age was 52 years (range, 12-85 years). The preoperative visual acuity was 20/1600 in 6 eyes (85.7%) and hand motions in 1 eye (14.3%). After a median follow-up period of 18 months (range, 3-30 months), the median final best spectacle-corrected visual acuity was 20/200 (range, 20/100 to light perception). This included 2 eyes (28.6%) that were 20/100 and 5 eyes (71.4%) that were better than 20/300. Compared with the preoperative best spectacle-corrected visual acuity, the final vision was improved in 6 eyes (85.7%) and worse in 1 eye (14.3%). The K-pro graft was retained in all 7 eyes (100%). The most common complication was the formation of a retroprosthetic membrane in 3 eyes (42.9%), none of which required either a YAG capsulotomy or a vitrectomy. One eye (14.3%) developed a wound dehiscence that required surgical repair.
CONCLUSIONS: The Boston K-pro type I is a good option for the visual rehabilitation of eyes with congenital aniridia.

Entities:  

Mesh:

Year:  2013        PMID: 23449480     DOI: 10.1097/ICO.0b013e318281724a

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.

Authors:  Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian
Journal:  Am J Ophthalmol       Date:  2019-11-12       Impact factor: 5.258

2.  [Aniridia syndrome: clinical findings, problematic courses and suggestions for optimization of care ("aniridia guide")].

Authors:  B Käsmann-Kellner; B Seitz
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

3.  [Stage-related therapy of congenital aniridia].

Authors:  B Seitz; B Käsmann-Kellner; A Viestenz
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

Review 4.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

5.  Clinical outcomes and visual prognostic factors in congenital aniridia.

Authors:  Adam Jacobson; Shahzad I Mian; Brenda L Bohnsack
Journal:  BMC Ophthalmol       Date:  2022-05-25       Impact factor: 2.086

Review 6.  Congenital Aniridia: Clinic, Genetics, Therapeutics, and Prognosis.

Authors:  Pedro Calvão-Pires; R Santos-Silva; F Falcão-Reis; A Rocha-Sousa
Journal:  Int Sch Res Notices       Date:  2014-10-29

7.  Results with the Boston Type I keratoprosthesis after Acanthamoeba keratitis.

Authors:  Albert Santos; Luzia Diegues Silva; Luciene Barbosa de Sousa; Denise de Freitas; Lauro Augusto de Oliveira
Journal:  Am J Ophthalmol Case Rep       Date:  2017-03-14

8.  Long-Term Anatomical and Functional Survival of Boston Type 1 Keratoprosthesis in Congenital Aniridia.

Authors:  Ariann Dyer; Alix De Faria; Gemma Julio; Juan Álvarez de Toledo; Rafael I Barraquer; Maria Fideliz de la Paz
Journal:  Front Med (Lausanne)       Date:  2021-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.